TimesSquare Capital Management LLC acquired a new position in TESARO Inc (NASDAQ:TSRO) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 262,676 shares of the biopharmaceutical company’s stock, valued at approximately $33,911,000. TimesSquare Capital Management LLC owned 0.48% of TESARO as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in TESARO by 5.7% in the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after buying an additional 195,590 shares during the period. Vanguard Group Inc. lifted its stake in shares of TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after purchasing an additional 62,104 shares during the period. State Street Corp lifted its stake in shares of TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock valued at $163,496,000 after purchasing an additional 177,057 shares during the period. BB Biotech AG lifted its stake in shares of TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock valued at $122,796,000 after purchasing an additional 53,408 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in shares of TESARO in the 2nd quarter valued at approximately $100,301,000.
Several analysts recently commented on TSRO shares. Robert W. Baird reaffirmed a “neutral” rating and issued a $125.00 price objective on shares of TESARO in a report on Monday, October 2nd. Cann reaffirmed a “buy” rating and issued a $199.00 price objective on shares of TESARO in a report on Friday, September 8th. BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 23rd. Citigroup reiterated a “buy” rating and set a $216.00 target price on shares of TESARO in a research report on Monday, September 11th. Finally, Oppenheimer reiterated a “buy” rating and issued a $199.00 target price on shares of TESARO in a research report on Sunday, September 10th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $159.39.
Shares of TESARO Inc (NASDAQ TSRO) opened at $84.98 on Wednesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73. TESARO Inc has a 12-month low of $79.03 and a 12-month high of $192.94.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The business had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. During the same quarter in the previous year, the firm posted ($1.72) earnings per share. The company’s quarterly revenue was up 740.3% compared to the same quarter last year. research analysts predict that TESARO Inc will post -8.16 earnings per share for the current year.
In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $1,171,300. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,421 shares of company stock worth $1,312,175. Company insiders own 34.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “TimesSquare Capital Management LLC Takes Position in TESARO Inc (TSRO)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://ledgergazette.com/2017/12/06/timessquare-capital-management-llc-acquires-shares-of-262676-tesaro-inc-tsro-2.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.